La multi ani 2015!

Viitoarea intalnire APLR - sambata 31 ianuarie 2015, ora 10:00-12:00, spital Obregia

Intalnirea lunara se reia pe 31 ianuarie 2015 cu tema: E X I S T E N T A

Prof.Dr. Aurel ROMILA

Sarbatori fericite!

Sarbatori  fericite si un An Nou plin cu spor,  sanatate si impliniri, impreuna cu  toti cei dragi!

Multi ani!!

Cu bucurie!
Mihaela Dumitru

​

Bucurie pentru toti

Sarbatoarea Craciunului sa va umple sufletele de bucurie, iubirea sa se reverse pentru toti si darurile divine sa va imbratiseze, sa fie acum cea mai frumoasa sarbatoare a tuturor, iar noul an sa va aduca numai sanatate, belsug, lumina si pace.

Cu mult drag,

Mariana Dumitru

http://player.vimeo.com/video/58611141?autoplay=1

Codul PIN invers !

Carmen Momnarcho-Habanera: ANDRE RIEU ÎN PERICOL !...

Nu va speriati nu e chiar asha ,but, who knows....
https://www.youtube.com/embed/EWD04qLscWs

Suport de curs PSIHOPATOLOGIE 2015 - Master UEB

 
link suport de curs Psihopatologie: Filozofia discernamantului

 
link suport de curs: Meloterapia

 











link suport de curs: Artterapia

Interesting Article from MDLinx

MDLinx  Internal Medicine 5 minutes to stay current Your Article Summary New medications for treatment of obesity: metabolic and cardiovascular effects Canadian Journal of Cardiology, 11/25/14 Pucci A, et al. – The management of obesity remains a major challenge. While hard clinical outcome benefit has yet to be established obesity pharmacotherapy may soon offer to address many of the challenges in the clinical management of obesity, although newer and better drug combinations, and more evidence of benefit from appropriately designed outcome trials, is needed. Dietary therapy often fails, while bariatric surgery although successful, is demanding and applicable to a limited number of patients. Drug therapy has had many setbacks over the past twenty years because of serious adverse effects; however several new drugs for the treatment of obesity are either licensed in some parts of the world, submitted for registration, or completing phase 3 trials. These include combinations (at low dose) of existing drugs e.g. bupropion + naltrexone (Contrave), phentermine + topiramate (Qsymia), higher doses of existing drugs licensed for other indications (liraglutide 3mg) and new entities (lorcaserin). Here, the authors discuss the challenges and opportunities for obesity pharmacotherapy, and review in detail the efficacy of the new drugs in terms of weight loss, and both desirable and potential undesirable cardiovascular and metabolic risk factors. Substantial barriers remain, even if the drugs are approved, in successfully integrating these agents into weight management practice, largely related to cost, patient acceptability and clinician willingness to be engaged in obesity treatment. Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. Other articles in Internal Medicine >> Click here to see the complete list Weight gain and associated factors in patients using newer antidepressant drugs General Hospital Psychiatry, 12/03/14 Prenatal exposure to antibiotics, cesarean section and risk of childhood obesity International Journal of Obesity, 11/14/14 High consumption of pulses is associated with lower risk of abnormal glucose metabolism in women in Mauritius Diabetic Medicine, 11/14/14

Interesting Article from MDLinx

MDLinx  Internal Medicine 5 minutes to stay current Your Article Summary Weight gain and associated factors in patients using newer antidepressant drugs General Hospital Psychiatry, 12/03/14 Uguz F, et al. – The aim of the present study was to examine weight gain and its association with clinical and sociodemographic characteristics in patients using newer antidepressants. The study results suggest that patients who take newer antidepressants might have significant problems related to body weight. Methods The study had a cross-sectional design. A total of 362 consecutive psychiatric patients taking antidepressant drugs for 6 to 36 months were included in the study. Results The prevalence rate of weight gain was 55.2%; 40.6% of the patients had a weight gain of 7% or more compared to the baseline. Overall, antidepressant use was significantly related to increased body weight. Specifically, citalopram, escitalopram, sertraline, paroxetine, venlafaxine, duloxetine and mirtazapine, but not fluoxetine, were associated with significant weight gain. Multivariate logistic regression analysis indicated that lower education status, lower body mass index at the onset of antidepressant use and family history of obesity were independent predictors of weight gain ≥7% compared to the baseline. Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. Other articles in Internal Medicine >> Click here to see the complete list Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: Outcome after long-term follow-up Psychiatry Research, 12/02/14 Depression, anxiety, antidepressant use, and cardiovascular disease among Hispanic men and women of different national backgrounds: results from the Hispanic Community Health Study/Study of Latinos Annals of Epidemiology , 11/14/14 Maternal use of selective serotonin reuptake inhibitors and risk of miscarriage - assessing potential biases Paediatric and Perinatal Epidemiology, 11/12/14

Interesting Article from MDLinx

MDLinx  Psychiatry 5 minutes to stay current Your Article Summary Antidepressants and the risk of hyponatraemia: A class-by-class review of the literature Psychosomatics, 09/15/14 De Picker L, et al. – The study aimed to determine the relationship between hyponatraemia and antidepressants, defining incidence and odds ratios (ORs) for antidepressant classes. The authors conclude that hyponatraemia is a potentially dangerous side effect of antidepressants, not exclusive to SSRIs. Current evidence suggests a relatively higher risk of hyponatraemia with SSRIs and venlafaxine, especially combined with patient risk factors, warranting clinicians to be aware of this complication. The risks associated with mirtazapine and TCAs are moderate, supporting these antidepressants as alternative treatments for patients with (an increased risk of) hyponatraemia. Methods A review of the literature published until March 2013 was performed using Web of Science and PubMed employing combinations of search strings "antidepressants" and antidepressant class and generic drug names with "hyponatr(a)emia", "SIADH" or "inappropriate ADH". Results 21 effect studies and over 100 case reports were considered, the majority concerning SSRIs. Because of variations in study designs, populations and cut-off values, incidence rates diverged between 0.06-40% for SSRIs and 0.08-70% for venlafaxine. Although based on less solid evidence, incidence figures for mirtazapine and TCAs were lower. Regarding classes, ORs for SSRIs (1.5-21.6) were consistently higher than for TCAs (1.1-4.9). The risks associated with MAO inhibitors, reboxetine and bupropion could not be established due to insufficient information. Patient risk factors included older age (OR 6.3) and concomitant use of (thiazide) diuretics (OR 11.2-13.5). Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. Other articles in Psychiatry >> Click here to see the complete list 140 mmol/L of sodium versus 77 mmol/L of sodium in maintenance intravenous fluid therapy for children in hospital (PIMS): a randomised controlled double-blind trial The Lancet, 12/02/14 Hyponatraemia on admission to hospital is associated with increased long-term risk of mortality in survivors of myocardial infarction European Journal of Preventive Cardiology, 11/17/14 Fluid and electrolyte balance in children Anaesthesia & intensive care medicine, 11/10/14

Interesting Article from MDLinx

MDLinx  Psychiatry 5 minutes to stay current Your Article Summary Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study Journal of Affective Disorders, 07/17/14 Lopresti AL, et al. – Curcumin, the principal curcuminoid derived from the spice turmeric, influences several biological mechanisms associated with major depression, namely those associated with monoaminergic activity, immune–inflammatory and oxidative & nitrosative stress pathways, hypothalamus–pituitary–adrenal (HPA) axis activity and neuroprogression. Partial support is provided for the antidepressant effects of curcumin in people with major depressive disorder, evidenced by benefits occurring 4 to 8 weeks after treatment. Methods In a randomised, double-blind, placebo-controlled study, 56 individuals with major depressive disorder were treated with curcumin (500 mg twice daily) or placebo for 8 weeks. The primary measure was the Inventory of Depressive Symptomatology self-rated version (IDS-SR30). Secondary outcomes included IDS-SR30 factor scores and the Spielberger State-Trait Anxiety Inventory (STAI). Results From baseline to week 4, both curcumin and placebo were associated with improvements in IDS-SR30 total score and most secondary outcome measures. From weeks 4 to 8, curcumin was significantly more effective than placebo in improving several mood-related symptoms, demonstrated by a significant group x time interaction for IDS-SR30 total score (F1,53=4.22, p=.045) and IDS-SR30 mood score (F1,53=6.51, p=.014), and a non-significant trend for STAI trait score (F1,48=2.86, p=.097). Greater efficacy from curcumin treatment was identified in a subgroup of individuals with atypical depression. Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. Other articles in Psychiatry >> Click here to see the complete list Serum dehydroepiandrosterone sulfate and incident depression in the elderly: The Pro.V.A Study The American Journal of Geriatric Psychiatry, 11/21/14 Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: Outcome after long-term follow-up Psychiatry Research, 12/02/14 Depression, anxiety, antidepressant use, and cardiovascular disease among Hispanic men and women of different national backgrounds: results from the Hispanic Community Health Study/Study of Latinos Annals of Epidemiology , 11/14/14

Interesting Article from MDLinx

MDLinx  Psychiatry 5 minutes to stay current Your Article Summary Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: Randomized double-blind placebo-controlled study Journal of Psychiatric Research, 03/14/14 Modabbernia A, et al. – The authors aimed to determine the efficacy of melatonin 3 mg/day in prevention of olanzapine–induced metabolic side–effects. In patients treated with olanzapine, short–term melatonin treatment attenuates weight gain, abdominal obesity, and hypertriglyceridemia. It might also provide additional benefit for treatment of psychosis. Methods In a randomized double-blind placebo-controlled study, 48 patients with first-episode schizophrenia who were eligible for olanzapine treatment, were randomly assigned to olanzapine plus either melatonin 3 mg/day or matched placebo for eight weeks. Anthropometric and metabolic parameters as well as psychiatric symptoms using The Positive and Negative Syndrome Scale (PANSS) were assessed at baseline, week 4, and 8. Primary outcome measure was the change from baseline in weight at week 8. Results Data were analyzed using t-test, Mann–Whitney U test, and mixed-effects model. Thirty-six patients had at least one post-baseline measurement. At week eight, melatonin was associated with significantly less weight gain [mean difference (MD)=3.2 kg, P=0.023], increase in waist circumference [MD=2.83 cm, P=0.041] and triglyceride concentration [MD=62 mg/dl, P=0.090 (nearly significant)] than the placebo. Changes in cholesterol, insulin, and blood sugar concentrations did not differ significantly between the two groups. Patients in the melatonin group experienced significantly more reduction in their PANSS scores [MD=12.9 points, P=0.014] than the placebo group. No serious adverse events were reported. Author Commentary Exclusive Amirhossein Modabbernia 03/18/2014 Olanzapine is one of the most effective antipsychotics, but at the same time is associated with high frequency of weight gain and several other metabolic disturbances. The results of this study underscore the efficacy of low dose melatonin in preventing weight gain and hypertriglyceridemia following olanzapine treatment. Unlike several other medications used to counteract the metabolic side effects of olanzapine, melatonin is associated with minimal side effects. Interestingly and unexpectedly we also show an additional antipsychotic effect of melatonin in treatment of schizophrenia, a finding that needs to be replicated in future studies. Importantly, our results are confined to short term treatment and long term effects of melatonin treatment in patients taking olanzapine has not been studied yet. Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. Other articles in Psychiatry >> Click here to see the complete list Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study JAMA Internal Medicine, 11/14/14 Emergency and critical care management of acute ischaemic stroke CNS Drugs, 11/25/14 Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: A systematic review and meta-analysis of randomised clinical trials European Journal of Preventive Cardiology, 11/26/14

Interesting Article from MDLinx

MDLinx  Psychiatry 5 minutes to stay current Your Article Summary Zolpidem and the risk of Parkinson's disease: A nationwide population-based study Journal of Psychiatric Research, 08/01/14 Yang YW, et al. – This nationwide population–based study investigated the risk of Parkinson's disease (PD) after zolpidem use in patients with sleep disturbance using the National Health Insurance Research Database (NHIRD) in Taiwan. Among the patients with sleep disturbance, zolpidem use increased the risk of PD after 5 years of follow–up. Further mechanistic research of zolpidem effect in PD is needed. Methods In total, 59548 adult patients newly diagnosed with sleep disturbance and who used zolpidem were recruited as the study cohort, along with 42171 subjects who did not use zolpidem as a comparison cohort from 2002 to 2009. Each patient was monitored for 5 years, and those who subsequently had PD were identified. A Cox proportional hazards model was used to compare the risk of PD between the study and comparison cohorts after adjusting for possible confounding risk factors. Results The patients who received zolpidem had a higher cumulative rate of PD than those who did not receive zolpidem during the 5-year follow-up period (1.2% vs. 0.5%, P < 0.001). The adjusted hazard ratios were 1.10 (95% CI, 0.88 to 1.37), 1.41(95% CI, 1.17 to 1.72), and 1.27 (95% CI, 1.05 to 1.55) for zolpidem use with 28 to 90, 91 to 365, and more than 365 cumulative defined daily doses (cDDDs), respectively, compared to those who did not use zolpidem. Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. Other articles in Psychiatry >> Click here to see the complete list The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: A double-blind, randomized, placebo-controlled trial Schizophrenia Research, 11/26/14 Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: An integrated analysis of 15 clinical trials Journal of Psychopharmacology, 12/01/14 Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment Journal of Clinical Oncology, 12/03/14

Editorial decembrie 2014 - Prof.Dr. Aurel ROMILA

                    F O R M U L E  PENTRU  PSIHOTERAPIE

Una din contributiile seminarelor lunare APLR este discutarea unor formule pentru psihoterapie. Ideea deriva din website-ul: aplr-doctorat.blogspot.com cu tema "FILOZOFIA DISCERNAMANTULUI".

Am ales pentru acest editorial formule legate de relatia EGO-SINE.

Seria ordonata ar putea fi;
      
       Normal = EGO – SINE

Din care putem obtine: 
    
     Ego fara Sine = OLIGOFRENIE; 

     Sine fara Ego = SCHIZOFRENIE; 

     Sine cu Ego sufernid = NEVROZA; 

     Ego cu Sine impotriva celorlalti = PSIHOPATIE;
     si 
    Ego transformat prin pierderea Sinelui = DEMENTA. 


Astept parerile voastre.

 Pentru mai multe detalii vedeti LECTIILE de la Revista.


Prof.Dr. Aurel ROMILA 

Destine interesante.;Anastasia Romanov;...Imparateasa Sissi;.Maria de Romania;..Zenobia/Woman who changed the world

• Anastasia Romanov
• Anne Boleyn
• Anne a Marii Britanii
• Boudicca
• Caterina de Medici Caterina Sforza
• Cleopatra
• Diane de Poitiers
• Ecaterina cea Mare
• Elisabeta Feodorovna
• Elizabeth Bathory
• Elizabeth I
• Elisabeta a II-
• Emma Hamilton
• Împărăteasa Sissi
• Eva Braun
• Georgiana Cavendish
• Giulia Gonzaga
• Godiva
• Guinevere
• Elena din Troia
• Hürrem Sultan
• Ioana d Arc
• Isabella de Castilia
• Josephine de Beauharnais
• Kriemhild
• Lady DI
• Lucrezia Borgia
• Madame de Pompadour
• Madame Roland
• Marguerite de Valois
• Maria de România
• Maria Stuart
• Maria Tereza
• Maria Tudor
• Marie Antoinette
• Mata Hari
• Messalina
• Nefertiti
• Pope Joan
• Regina din Saba
• Teodora Împărăteasa
• Victoria a Angliei
• Zenobia | Women who changed the world

LEGILE DESTINULUI

- prima lege zice: "Persoanele pe care le intalnesti sunt  persoanele potrivite". Cu alte cuvinte, nimeni nu intra in viata noastra din intamplare; toate persoanele cu care interactionam se afla alaturi de noi cu un motiv, acela de a ne ajuta sa invatam lectiile de viata care apar si sa continuam drumul personal;
- a doua lege zice: "Ceea ce ni se intampla este singurul lucru care ni se putea intampla". Nimic, absolut nimic din ceea ce se produce in viata noastra nu ar fi putut sa se intample in alt mod (nici macar detaliul cel mai nesemnificativ)… Nu exista: "daca as fi facut cutare lucru….s-ar fi produs alt cutare lucru…." NU. Toate si fiecare in parte dintre situatiile care se produc sunt perfecte, cu toate ca mintea si egoul nostru nu le accepta …
- a treia lege zice: "Orice moment in care se incepe este momentul corect". Totul incepe in momentul potrivit, nici inainte, nici dupa; cand suntem pregatiti pentru ca ceva nou sa apara in viata noastra, exact atunci apare (incepe);
- a patra lege zice: "Cand ceva se termina, se termina". Daca ceva a luat sfarsit in viata noastra, este pentru propria noastra evolutie, deci cel mai bine este sa inchizi capitolul si sa mergi inainte imbogatit cu acea experienta.
 
Cred ca nu este intamplator ca citesti aceste randuri acum; acest text ajunge la tine azi pentru ca esti pregatit(a) sa intelegi ca  "nici un fulg de zapada nu cade niciodata in locul gresit"…